請不要太高興，這個治療是在萬般無奈時使用的療法。
The effectiveness of Provenge was studied in 512 patients with metastatic
hormone treatment refractory prostate cancer in a randomized, double-blind,
placebo-controlled, multicenter trial, which showed an increase in overall
survival of 4.1 months. The median survival for patients receiving Provenge
treatments was 25.8 months,
as compared to 21.7 months for those who did not receive the treatment.
只比接受非此項治療的病人多活4.1個月
總體生存時間（通常是中位數）25.8個月
本來平均可以活到接近兩年，用了這個治療可以活到2年多一個月
而且細胞治療，其實有很大的安全性問題，需要GTP來規範。
※ 引述《rnwk (rnwk)》之銘言：
: FDA Approves a Cellular Immunotherapy for Men
: with Advanced Prostate Cancer
: http://seattletimes.nwsource.com/ABPub/2010/04/29/2011734943.pdf
--
A whole new world is coming with novel treatment of CML
嶄新的治療，讓慢性骨髓白血病的新世界到來
CML Club, Share Your Experience
到慢性骨髓性白血病交流園地，分享你的經驗
http://www.cml.club.tw
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 140.112.125.74